50% ~75% of patients with chronic kidney disease (CKD) have hypertension. Studies have confirmed that the blood pressure status of patients with CKD is closely related to their long-term prognosis. At present, calcium channel blocker (CCB), angiotensin converting enzyme inhibitors (ACEI), angiotensin Ⅱ receptor blocker (ARB), β-adrenergic receptor blocker (β-receptor blocker), diuretics, etc. are the main drugs for clinical treatment of hypertension in patients with CKD. However, clinical practice has found that it is still difficult for some patients with CKD to reach the blood pressure standard after sufficient doses and combined use of antihypertensive drugs. Therefore, new therapeutic approaches should be sought for refractory hypertension that is still difficult to control after more than 2 weeks of treatment with sufficient doses and combined application of more than 3 antihypertensive drugs.
